<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086541</url>
  </required_header>
  <id_info>
    <org_study_id>IRHC-001</org_study_id>
    <secondary_id>DIRECT 1</secondary_id>
    <nct_id>NCT00086541</nct_id>
  </id_info>
  <brief_title>Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa Plus Ribavirin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <brief_summary>
    <textblock>
      This Phase 3 clinical study is designed to evaluate the safety, tolerability, and efficacy of&#xD;
      two dose levels of Infergen (interferon alfacon-1, CIFN) plus Ribavirin administered daily&#xD;
      for 48 weeks and no treatment in patients chronically infected with hepatitis C who are&#xD;
      nonresponders to previous pegylated interferon alfa plus ribavirin therapy.&#xD;
&#xD;
      Patients are randomized 1:1:1 to receive Interferon Alfacon-1 (9 or 15 µg) + Ribavirin (both&#xD;
      administered daily) or no treatment for up to 48 weeks.&#xD;
&#xD;
      The protocol and informed consent form that will be used must be approved by the&#xD;
      Investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC) before the&#xD;
      study is initiated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate sustained virologic response (SVR) rate of daily Infergen at two dose levels plus ribavirin and no treatment in chronically HCV-infected patients who are nonresponders to previous pegylated interferon alfa plus ribavirin therapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety &amp; tolerability of therapy detailed in primary objective, and proportion of patients with (a) undetectable plasma HCV RNA levels at weeks 24 &amp; 48 (b) abnormal baseline serum ALT levels that are normal at week 24, week 48 and weeks 48 &amp; 72.</measure>
  </secondary_outcome>
  <enrollment type="Actual">515</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        (Abbreviated due to space constraints.)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form&#xD;
&#xD;
          2. Male or female 18 yrs. of age or older&#xD;
&#xD;
          3. Chronic HCV infection based on documented history of positive serum anti-HCV antibody&#xD;
             test and/or detectable levels of HCV RNA&#xD;
&#xD;
          4. Documented virologic nonresponse to past treatment with PEGASYS plus ribavirin or&#xD;
             PEG-Intron plus ribavirin&#xD;
&#xD;
          5. Previously treated w/either of the following starting doses of pegylated interferon&#xD;
             alpha:&#xD;
&#xD;
               1. ≥ 1.5 µg/kg/week PEG-Intron or dose consistent with the package insert or,&#xD;
&#xD;
               2. ≥ 180 µg/week PEGASYS&#xD;
&#xD;
          6. Detectable plasma HCV RNA level at screening visit&#xD;
&#xD;
          7. Liver biopsy histologically documenting chronic liver disease consistent with chronic&#xD;
             HCV infection&#xD;
&#xD;
          8. All patients and all potentially fertile sexual partners of patients must use 2&#xD;
             reliable forms of effective contraception during the study &amp; for 6 months after&#xD;
             cessation of the study drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any history of decompensated liver disease&#xD;
&#xD;
          2. Any of a variety of laboratory abnormalities assessed through blood sample at&#xD;
             screening&#xD;
&#xD;
          3. Patients who prematurely discontinued, interrupted, or reduced the dose of their&#xD;
             previous pegylated interferon alpha-based combination therapy due to noncompliance or&#xD;
             safety and/or tolerability issues&#xD;
&#xD;
          4. Patients who had undetectable HCV RNA levels during prior pegylated interferon alfa&#xD;
             plus ribavirin treatment but who relapsed during follow-up&#xD;
&#xD;
          5. Significant depression in the last 2 years&#xD;
&#xD;
          6. Patients treated for HCV infection within 3 months before screening (w/the exclusion&#xD;
             of over-the-counter therapies)&#xD;
&#xD;
          7. Patients who have been on any experimental protocol or therapy within 28 days before&#xD;
             screening&#xD;
&#xD;
          8. Use of colony-stimulating factor agents or other therapeutic agents that might&#xD;
             artificially elevate laboratory parameters within 3 months before screening&#xD;
&#xD;
          9. Known human immunodeficiency virus (HIV) infection or positive HIV antibody test at&#xD;
             screening&#xD;
&#xD;
         10. Chronic hepatitis B infection or positive hepatitis B surface antigen (HBsAg) at&#xD;
             screening&#xD;
&#xD;
         11. New onset diabetes&#xD;
&#xD;
         12. Unstable or uncontrolled thyroid disease&#xD;
&#xD;
         13. Presence or history of non-HCV chronic liver disease&#xD;
&#xD;
         14. History of unstable or deteriorating cardiac or cerebrovascular disease within 6&#xD;
             months before Screening&#xD;
&#xD;
         15. Current or history of neurologic disorder within the last 2 years&#xD;
&#xD;
         16. History of seizures within the past 5 years&#xD;
&#xD;
         17. History of hemoglobinopathies&#xD;
&#xD;
         18. History of malignancy within the last 5 years with the exception of localized basal or&#xD;
             squamous cell carcinoma &amp; fully resected, localized malignancy not requiring active&#xD;
             treatment &amp; with no evidence of recurrence&#xD;
&#xD;
         19. A disease known to cause significant alteration in immunologic function including&#xD;
             hematologic malignancy, sarcoidosis or autoimmune disorder&#xD;
&#xD;
         20. History or evidence of retinopathy&#xD;
&#xD;
         21. History of major organ transplantation with an existing functional graft&#xD;
&#xD;
         22. Concurrent therapy with immunosuppressive drugs or cytotoxic agents&#xD;
&#xD;
         23. Alcohol and/or drug abuse w/in the past year, that in the opinion of the Investigator&#xD;
             or the Sponsor may negatively affect patient compliance&#xD;
&#xD;
         24. Pregnant or lactating women&#xD;
&#xD;
         25. Male partners of women who are pregnant&#xD;
&#xD;
         26. Known sensitivity to Infergen or IFN-α or to E. coli-derived products&#xD;
&#xD;
         27. Patients who, in the opinion of the Investigator or the Sponsor, are not suitable&#xD;
             candidates for enrollment or who would not comply w/the requirements of the study&#xD;
&#xD;
         28. Patients who have not responded to a course of daily Infergen (9 or 15 µg) with or&#xD;
             without ribavirin or who have relapsed after a course of daily Infergen (9 or 15 µg).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph T. Doyle</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.directtrial.com</url>
    <description>Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 2, 2004</study_first_submitted>
  <study_first_submitted_qc>July 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2004</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Liver</keyword>
  <keyword>Pegylated</keyword>
  <keyword>Interferon</keyword>
  <keyword>Alpha</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Combination</keyword>
  <keyword>Nonresponder</keyword>
  <keyword>HCV</keyword>
  <keyword>Infergen</keyword>
  <keyword>SVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon alfacon-1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

